MAINTENANCE THERAPY IN STAGES IIIB-IV NON-SMALL-CELL LUNG CANCER
- Authors: Gutorov SL1, Borisova Y.I1, Gutorov S.L.1, Borisova E.I.1
-
Affiliations:
- Issue: No 17 (2010)
- Pages: 51-55
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278667
- ID: 278667
Cite item
Full Text
Abstract
The article is dedicated to the modern features of maintenance therapy in patients with IIIB-IV stages non-small-cell lung cancer. As a supportive treatment, use of drugs included in regimen of induction therapy may be continued, and administration of new drug with other mechanisms of action and spectrum of side effects is feasible. After a standard induction treatment (4 to 6 courses of chemotherapy, doublet regimen with the inclusion of platinum derivatives), maintenance therapy can be performed in the absence of disease progression. This treatment is particularly effective against the background of achieving stabilization of disease. Maintenance therapy can be appointed until disease progression or development of unacceptable toxicity. Currently, pemetrexed or erlotinib can be applied in non-small-cell lung cancer; docetaxel, gemcitabine, and erlotinib in squamous cell cancer. In the case of use of bevacizumab in the induction treatment, it is reasonable to continue maintenance treatment with this drug, possibly in combination with erlotinib (bevacizumab in combination of with chemotherapy as a maintenance treatment is studied).
References
- Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:1335-43.
- Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-40.
- Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2009;27(18S):CRA8000.
- Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155-63.
- Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. Program and abstracts of the 2010 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2010; Chicago, Illinois. Abstract 7507.
- ССО, Clinical Considerations and the Evolving Role of Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer Beth Eaby-Sandy, MSN, CRNP, OCN, Victoria Sherry, MSN, CRNP, AOCNP, Mark Socinski, MD, Howard (Jack) L. West, MD
- Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-98.
- Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced nonsmall-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-29.
- Sandler A, Gray R, Perry MC, et al. Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N Engl J Med 2006;355:2542-50.
- Kabbinavar FF, Miller VA, Johnson BE, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2010; Chicago, Illinois. 7526
Supplementary files
